Once-daily mesalamine granules for ulcerative colitis

References

• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology126(6), 1504–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Svartz N. The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa. Acta Med. Scand.131(Suppl. 206), 465–472 (1948).
   PubMedGoogle Scholar
• Svartz N. Treatment of ulcerative colitis with salazopyrin. Int. Surg.50(5), 421–427 (1968).
   PubMedGoogle Scholar
• Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N. Engl. J. Med.289(10), 491–495 (1973).
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet2(8044), 892–895 (1977).
   PubMed Web of Science ®Google Scholar
• Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs68(8), 1089–1103 (2008).
   PubMedGoogle Scholar
• Brunner M, Greinwald R, Kletter K et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment. Pharmacol. Ther.17(9), 1163–1169 (2003).
   PubMed Web of Science ®Google Scholar
• Brunner M, Assandri R, Kletter K et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther.17(3), 395–402 (2003).
   PubMed Web of Science ®Google Scholar
• Safdi A, Pieniaszek H, Grigston A, Forbes W. Multiple dose pharmacokinetics of granulated mesalamine, a unique formulation providing delayed and extended release of 5-ASA. Am. J. Gastroenterol.103(A1126), S439 (2008).
   Web of Science ®Google Scholar
• Wiersma H, Escher JC, Dilger K et al. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm. Bowel Dis.10(5), 626–631 (2004).
   PubMed Web of Science ®Google Scholar
• Wilding IR, Behrens C, Tardif SJ, Wray H, Bias P, Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment. Pharmacol. Ther.17(9), 1153–1162 (2003).
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment. Pharmacol. Ther.24(Suppl. 1), 2–9 (2006).
   PubMed Web of Science ®Google Scholar
• Dubuquoy L, Rousseaux C, Thuru X et al. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut55(9), 1341–1349 (2006).
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Lefebvre B, Dubuquoy L et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ. J. Exp. Med.201(8), 1205–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther.17(1), 29–42 (2003).
   PubMed Web of Science ®Google Scholar
• Safdi A, Pieniaszek H, Grigston A, Forbes W. Minimal effect of a high-fat meal on the pharmacokinetics of once-daily, granulated mesalazine. Am. J. Gastroenterol.103(A1127), S440 (2008).
   Web of Science ®Google Scholar
• Zakko S, Gordon GL, Murthy U et al. Once-daily mesalamine granules effectively maintain remission from ulcerative colitis: data from two Phase 3 trials. Gastroenterology136(5), 252, T1202 (2009).
   Google Scholar
• Sutherland LR, Martin F, Greer S et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology92(6), 1894–1898 (1987).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR. Once-daily 1.5g granulated mesalamine effectively maintains remission in patients with ulcerative colitis who switch from different 5-ASA formulations. Am. J. Gastroenterol.103(S1), 429–430 (2008).
   Web of Science ®Google Scholar
• Lichtenstein G, Merchant K, Shaw A, Yuan J, Bortey E, Forbes W. Efficacy of mesalamine granules for maintenance of remission in patients recently treated with corticosteroids. Gastroenterology136(5,Suppl. 1), T1204 (2009).
   Google Scholar
• Kruis W, Bar-Meir S, Feher J et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin. Gastroenterol. Hepatol.1(1), 36–43 (2003).
   PubMed Web of Science ®Google Scholar
• Marakhouski Y, Fixa B, Holoman J et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment. Pharmacol. Ther.21(2), 133–140 (2005).
   PubMed Web of Science ®Google Scholar
• Kruis W, Kiudelis G, Racz I et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double dummy, randomised, non-inferiority trial. Gut58(2), 233–240 (2009).
   PubMed Web of Science ®Google Scholar
• Zakko S, Murthy U, Pruitt R et al. Safety profile of once daily 1.5 g granulated mesalamine as maintenance therapy for mild-to-moderate ulcerative colitis: results from 2 Phase 3 trials. Am. J. Gastroenterol.103(S437), 1119 (2008).
   Web of Science ®Google Scholar
• Gordon G, Zakko S, Murthy U et al. Long-term safety of once-daily 1.5 g mesalamine granules in patients in remission from ulcerative colitis. Gastroenterology136(5, Suppl. 1), A521 (T1200) (2009).
   Google Scholar
• Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin. Drug Saf.6(2), 99–107 (2007).
   PubMed Web of Science ®Google Scholar
• Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review. Pediatr. Nephrol.19(5), 550–553 (2004).
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med.114(1), 39–43 (2003).
   PubMed Web of Science ®Google Scholar
• Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig. Dis. Sci.53(4), 1020–1024 (2008).
   PubMed Web of Science ®Google Scholar
• Kane S. A 38-year-old with recurrent colitis. Is it noncompliance? Clin. Gastroenterol. Hepatol.7(11), 1164–1167 (2009).
   PubMedGoogle Scholar
• Dignass AU, Bokemeyer B, Adamek H et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin. Gastroenterol. Hepatol.7(7), 762–769 (2009).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Korzenik J, Lashner B et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology138(4), 1286–1296 (2010).
   PubMed Web of Science ®Google Scholar
• Ito H, Iida M, Matsumoto T et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm. Bowel Dis. DOI: 10.1002/ibd.21194 (2010) (Epub ahead of print).
   Google Scholar
• Kruis W, Jonaitis L, Pokrotnieks J et al. Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology134(4, Suppl. 1, T1124), A-489 (2008).
   Google Scholar